Marker Therapeutics, Inc.
Marker Therapeutics, Inc. (MRKR): 7 pipeline candidates · 2 upcoming catalysts · ~35 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
34.6 months
D/E 0.26 · 16% dilution
Lead: Phase 2
7 candidates
2 upcoming, next in ~28d
N/A
A transparent, data-derived signal for Marker Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$22.3M
Cash
$15.6M
Quarterly Burn
$1.4M
Runway
34.6 mo
Revenue
$752K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| mt-401 | Phase 2 |
| mt-401-ots | Phase 2 |
| mt-601 | Phase 2 |
| mt-601 dose 1200 million cells | Phase 1 |
| mt-601 dose 200 million cells | Phase 1 |
| mt-601 dose 400 million cells | Phase 1 |
| mt-601 dose 800 million cells | Phase 1 |
Upcoming Catalysts (2)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
32
Total value held
$2.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 778,638 | $1.0M |
| renaissance technologies llc | 175,294 | $228K |
| geode capital management, llc | 160,910 | $209K |
| osaic holdings, inc. | 93,121 | $121K |
| vanguard fiduciary trust co | 87,269 | $113K |
| xtx topco ltd | 63,567 | $83K |
| two sigma investments, lp | 61,001 | $79K |
| susquehanna international group, llp | 48,780 | $63K |
| jane street group, llc | 36,303 | $47K |
| ubs group ag | 32,369 | $42K |
Showing top 10 of 32 institutional holders of Marker Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Marker Therapeutics, Inc.'s pipeline?
Marker Therapeutics, Inc. (MRKR) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Marker Therapeutics, Inc.'s lead drug candidate?
Marker Therapeutics, Inc.'s most advanced tracked candidate is mt-401 (Phase 2) for Acute Myeloid Leukemia.
What is Marker Therapeutics, Inc.'s next catalyst?
Marker Therapeutics, Inc.'s next tracked catalyst is a Phase1_Start event — "Phase 1 Start: A Phase 1 Study With Expansion of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (M" — expected July 16, 2026.
What is Marker Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Marker Therapeutics, Inc. has approximately 34.6 months of cash runway.
What is Marker Therapeutics, Inc.'s market capitalization?
Marker Therapeutics, Inc.'s market capitalization is approximately $22.3M.
Get the full picture on Marker Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.